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In October 2012, a maternal pertussis vaccination program 
was implemented in England following an increased incidence 
and mortality in infants. We evaluated the cost-effectiveness of 
the program by comparing pertussis-related infant hospitaliza-
tions and deaths in 2012–2017 with nonvaccination scenarios. 
Despite considerable uncertainties, findings support the cost-ef-
fectiveness of the program.
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Following sharply increased pertussis-related incidence and 
mortality in infants, a pertussis vaccination program for preg-
nant women was implemented in England in October 2012 as 
an outbreak control measure. The program has been highly ef-
fective in England in protecting infants in the first 2 months of 
life [1]. Maternal vaccination has the advantage of conferring 
passive protection to the fetus via transplacental transfer of anti-
bodies and of reducing maternal transmission to infants until 
they can be actively protected via primary immunizations [2].
In 2014, the Joint Committee on Vaccination and 
Immunisation agreed to continue the maternal program 
for a further 5  years, with a decision to be made in 2019 
about whether to maintain it as a routine program [1]. This 
postimplementation evaluation hence reports on the 6-year 
impact and cost-effectiveness of the existing maternal vacci-
nation program (as compared with nonvaccination scenarios) 
using high-quality enhanced surveillance data to inform 
policy making.
METHODS
Our cost-effectiveness analysis focused on pertussis-related 
hospitalizations and deaths in infants aged 0–2  months (ie, 
<3 months) in England between 2012 and 2017.
For the maternal vaccination program, we used the Hospital 
Episode Statistics (HES) database to observe the number of 
hospitalizations (Finished Admission Episodes) of pertussis 
(“whooping cough”; International Classification of Diseases, 
10th revision, code A37) in any diagnostic field for the pe-
riod October 2012–December 2017. For the nonvaccination 
scenarios, we considered 2 approaches to estimate the number 
of infant hospitalizations potentially prevented through the 
 maternal program:
 1. First, we applied the annual change in the number of hospi-
talizations (in age groups other than <3 months) after 2011 
to infants aged less than 3  months (Supplementary Table 
1). We considered the age groups of 3–11 months (ie, up to 
364 days; scenario S1), 6–11 months (S2), 1–2 years (S3), 
and 5–9 years (S4).
 2. Second, we back-estimated the annual number of hospital-
izations potentially seen without the maternal program based 
on the observed number of hospitalizations in inpatients 
aged less than 3  months, the estimated vaccine effective-
ness (VE) in infants (0.91) [1], and the annual(ized) vaccine 
coverage based on 2 data sources (ImmForm, S5; Clinical 
Practice Research Datalink [CPRD], S6):
Estimated inpatients = Observed inpatients
/ (1 − VE ∗ coverage)
ImmForm is a routinely collected extraction of records in more 
than 90% of general practitioner (GP) practices in England; 
CPRD is a representative sentinel dataset of approximately 5% 
of GP practices in England. Following a change in how the data 
were extracted from ImmForm in April 2016, the reported cov-
erage increased and aligned more closely to the estimates from 
CPRD, suggesting that ImmForm had previously underesti-
mated coverage [1]. General practitioner datasets were used as 
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In terms of mortality, with the maternal vaccination program 
in place, 17 deaths occurred due to pertussis in infants aged less 
than 3  months born between October 2012 and December 
2017 [1]. Of these, 2 were to mothers who were vaccinated 
but too near to birth to confer passive protection (15 were to 
unvaccinated mothers). For all nonvaccination scenarios (ie, 
S1–S6), the number of infant deaths was extrapolated based on 
the estimated number of hospitalizations and the case-fatality 
risk (CFR) for hospitalized infants aged less than 3 months in 
England from before the vaccination program was introduced 
(16/513 = 0.0312 between October 2011 and September 2012 
[4]). We conservatively assumed that the infant CFR without 
the maternal vaccination program would not have returned to 
preresurgence levels given the continued and exclusive use of 
acellular pertussis vaccines in England since 2004, which are 
thought to have contributed to the resurgence of severe cases 
and deaths in infants and the elevated disease activity seen 
across all ages ever since 2012 due to diminished indirect pro-
tection from infection [1, 5]. In a scenario analysis, however, 
we explored the return of the CFR to preresurgence levels even 
without having adopted the maternal program.
For both the vaccination program and the nonvaccination 
scenarios, we assumed infants lost 0.10070 quality-adjusted 
life-years (QALYs) per hospitalization [4] and 25.6 versus 
42.6 QALYs per fatality when discounting at 3.5% versus 1.5% 
(which were estimated from official statistics of life expectancy 
at birth in England in 2012–2017 and the estimated population 
norms of the quality of life in England by sex and age [6]).
We considered the costs of hospitalizations and the vaccina-
tion program to the National Health Service (NHS) in England. 
The hospitalization costs were based on NHS reference costs 
for 2012–2013 to 2017–2018 (Supplementary Table 2). The 
data were obtained for 2006–2017 from HES and the Pediatric 
Intensive Care Audit Network (PICANet), and we used the data 
predating the maternal vaccination program for extrapolation 
of the nonvaccination scenarios in 2012–2017 (Supplementary 
Table 3).
For the costs of vaccination, we considered the published in-
dicative list price of the vaccine and the annual service payment 
for administering the vaccine [7, 8]. The unit cost per patient 
was conservatively multiplied with the annual coverage rates of 
the higher estimates of CPRD [1] and the annual number of of-
ficially recorded maternities in England in 2012–2017 [9].
Since this was a postimplementation economic evaluation, 
we discounted all QALYs and costs back to the base year of the 
immunization program introduction in 2012 [10].
RESULTS
With the maternal vaccination program, the annually observed 
number of hospitalizations of pertussis inpatients aged less 
than 3 months was a mean of 207 in 2013–2017 (231 when an-
nualizing over October 2012–2017) (Figure 1A), while the CFR 
was a mean of 17 divided by 1211 = 0.014 between October 
2012 and December 2017.
For the nonvaccination scenarios, the estimated abso-
lute numbers of hospitalizations differed each year, but the 
trend over time in terms of peaks and troughs was similar 
across nonvaccination scenarios (S1–S6) and between the 
nonvaccination scenarios and the observed number of hospi-
talizations (Figure 1A). The similar trends suggest no sudden 
change had the program not been adopted, providing some 
reassurance for the validity of the back-estimated scenarios S5 
and S6.
Depending on the nonvaccination scenario, the maternal vac-
cination program was estimated to have prevented 1400–4300 
infant hospitalizations in 2012–2017, at net economic costs of 
£50-£58 million (discounted at 3.5%) or £53-£62 million (dis-
counted at 1.5%) (Figure 1B). These costs reflect both decreased 
expenditures on infant hospitalizations and additional expend-
itures on vaccination (Figure 1B).
In terms of fatalities and QALYs, the maternal vaccination 
is estimated to have prevented 82–170 infant deaths and 2100–
4500 or 3500–7500 infant QALY losses (discounted at 3.5% or 
1.5%, respectively) (Figure 1C). Assuming the CFR to have re-
turned to preresurgence levels even without maternal immuni-
zation, the program would have prevented an estimated 41–96 
infant deaths and 1100–2700 or 1800–4400 infant QALY losses 
(discounted at 3.5% or 1.5%, respectively).
Overall, the incremental costs per QALY gained from the 
program versus the nonvaccination scenarios ranged between 
£11 000–£28 200/QALY and £7000–£17 700/QALY when 
discounting at 3.5% and 1.5%, respectively (Figure  1D). The 
changes seen in the incremental cost-effectiveness ratios over 
time reflect the cyclical nature of pertussis (Figure  1A), with 
peaks occurring every 3–4 years in England [1]. These values 
increased to £18 400–£52 000/QALY and £12 100–£33 500/
QALY when assuming the CFR would have returned to 
preresurgence levels even without having adopted the maternal 
program (Supplementary Figure 1).
DISCUSSION
In England, introducing the maternal pertussis vaccination pro-
gram appears to have been cost-effective in reducing the annual 
number of infant hospitalizations and deaths between 2012 and 
2017 up to the published list prices of the vaccines, despite con-
siderable uncertainties regarding the outcomes.
Our study focused on the most important cost factors from 
the NHS perspective, while ignoring the direct protection 
for vaccinated pregnant women and the resultant cocooning 
effect that may help reduce infection even after infant vacci-
nation begins [1]. Our focus on infant hospitalizations seems 
justified given the high proportion of pertussis-confirmed in-
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Figure 1. Findings of the postimplementation evaluation of the maternal pertussis vaccination program in England, 2012–2017, showing the observed versus estimated 
number of hospitalizations in infants aged less than 3 months annually (A); the total costs of the maternal program with the observed versus estimated number of hospital-
izations without the program (B); the total infant QALY loss under the maternal program with the observed versus estimated total infant QALY loss without the program (C); 
and the cumulative incremental costs per QALY gained from the maternal program versus the nonvaccination program scenarios (D).
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For the nonvaccination scenarios S1–S4, scenario S4 (ages 
5–9 years) needs to be interpreted with caution given the low 
absolute numbers of hospitalizations and the resulting larger 
relative annual changes. Moreover, some of the younger infants 
within scenario S1 (ages 3–11  months) may still experience 
some residual protection from maternal immunization (pos-
sibly a cocooning effect), while those aged 6–11 months (sce-
nario S2) may experience diminished protection after primary 
vaccination due to blunting following maternal vaccination 
(despite no clinically significant blunting having been dem-
onstrated in England [1]). Furthermore, the back-calculated 
scenarios S5 and S6 may lack precision as they assumed no so-
cioeconomic gradient for both disease risk and coverage [12]; 
an exploratory scenario analysis by region resulted in slightly 
higher incremental cost-effectiveness ratios (Supplementary 
Table 4).
Our analysis did not account for long-term disability in pe-
diatric intensive care unit survivors [13] or explore additional 
parameter uncertainty, had a retrospective 6-year time frame 
only, and did not explicitly model transmission dynamics [5]. 
Contrasting 2 discount rates also helps illustrate their different 
impact on QALYs lost per infant death. Ongoing research ex-
plores the impact of implementing the program routinely.
In conclusion, despite the considerable uncertainties, our 
findings support the cost-effectiveness of the maternal per-
tussis vaccination program in England in 2012–2017 up to the 
published list prices of the vaccines (which are higher than the 
confidential, and hence unknown, tender prices paid by the 
NHS).
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